Elabela as a Novel Marker; Well-Correlated with WIfI Amputation Risk Score in Patients with Lower Extremity Arterial Disease

Kaplan, Mehmet; Yavuz, Fethi; Kaplan, Gizem; Bursa, Nurbanu; Vuruşkan, Ertan; Sucu, Murat

doi:10.14744/anatoljcardiol.2020.17329

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cho et al showed that high levels of this marker are visible from the earlier times of diabetic disease, before early symptoms [ 10 ]. Elabela peptide is a product of the renin-angiotensin-aldosterone system; Kaplan et al showed significant growth of this marker in patients with high grades of Rutherford and WIfi scale, with an increase in cardiovascular disease risk [ 31 ]. Passaro et al reported a study on 95 patients, where the homocysteine concentration, a biomarker known in the literature for its close link with vascular disease, is reduced by an improved metabolic control [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

The Role of Early Revascularization and Biomarkers in the Management of Diabetic Foot Ulcers: A Single Center Experience

et al. 2022

View full text Add to dashboard Cite

Diabetic neuropathy and Peripheral Arterial Disease (PAD) are the main etiological factors in foot ulceration. Herein, we report our experience of diabetic foot ulceration (DFU) management, with an analysis of the relationship between the rate of lower extremity amputation, in persons with infected DFU, after revascularization procedures performed to prevent major amputation. This study highlights the role of different biomarkers, showing their usefulness and potentiality in diabetic foot ulcer management, especially for the early diagnosis and therapy effectiveness monitoring. A retrospective analysis, from September 2016 to January 2021, of diabetic patients presenting diabetic foot with DFU, was performed. All patients were treated with at least one vascular procedure (endovascular, open, hybrid procedures) targeting PAD lesions. Outcomes measured were perioperative mortality and morbidity. Freedom from occlusion, primary and secondary patency, and amputation rate were registered. A total of 267 patients, with a mean age of 72.5 years, were included in the study. The major amputation rate was 6.2%, minor amputation rate was 17%. In our experience, extreme revascularization to obtain direct flow reduced the rate of amputations, with an increase in ulcer healing.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Early Revascularization and Biomarkers in the Management of Diabetic Foot Ulcers: A Single Center Experience

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In coronary artery disease, Yavuz et al found that there was a decrease in elabela concentrations in patients with chronic total occlusion of the coronary arteries and those with poor collateral development [30]. In patients with a lower-extremity arterial disease, the serum elabela levels are positively correlated with WIfI (Wound, Ischemia, foot Infection) amputation risk score and negatively correlated with ankle-brachial index [31]. From what has been discussed above, it can be established that elabela is a promising peptide that mediates a wide range of physiological and pathological processes of the vascular system and should be examined in future research.…”

Section: Elabela In Blood Vessel Regulationmentioning

confidence: 99%

Elabela: novel perspectives on vascular physiology and disease

Adiarto

Prakoso²

2022

Arterial Hypertension

View full text Add to dashboard Cite

Recently, a novel endogenous ligand of APJ called elabela has been identified to play an important role in cardiovascular development. Elabela and its G-protein-coupled receptor APJ are widely expressed throughout the human body. These have been identified to play a significant role in diverse biological processes, especially in the normal and pathological cardiovascular systems. In addition, increasing evidence indicates that elabela is also intimately associated with a large number of vascular physiological processes in adulthood, such as angiogenesis, vascular tone and atherosclerosis. However, a comprehensive summary of elabela in the vascular system has not been reported to date. In this review, we provide an overview of elabela in vascular physiology and diseases. Collectively, elabela, a potential biomarker and therapeutic peptide, exerts diverse biological vascular effects in adults.

show abstract

Elabela Peptide: An Emerging Target in Therapeutics

Sharma

Prabhavalkar

Bhatt

2022

CDT

View full text Add to dashboard Cite

Elabela, a bioactive micropeptide, is recognized as the second endogenous ligand for Apelin receptor and is widely distributed in different tissues and organs. Elabela plays important role in various physiological processes such blood pressure control, heart morphogenesis, apoptosis, angiogenesis, cell proliferation, migration, etc. Elabela is also implicated in pathological conditions like cardiac dysfunctions, heart failure, hypertension, kidney diseases, cancer and CNS disorders. The association of Elabela with these disease conditions makes it a potential target for their therapy. This review summarizes physiological role of Elabela peptide as well as its implication in various disease conditions.

show abstract

Elabela as a Novel Marker; Well-Correlated with WIfI Amputation Risk Score in Patients with Lower Extremity Arterial Disease

Cited by 3 publications

References 0 publications

The Role of Early Revascularization and Biomarkers in the Management of Diabetic Foot Ulcers: A Single Center Experience

The Role of Early Revascularization and Biomarkers in the Management of Diabetic Foot Ulcers: A Single Center Experience

Elabela: novel perspectives on vascular physiology and disease

Elabela Peptide: An Emerging Target in Therapeutics

Contact Info

Product

Resources

About